A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Overview of attention for article published in Cancers, August 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 12,883 followers.

New article: A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome https://t.co/ZDPyB29qNd #MDS #mdssm #hematology https://t.co/pHp6HptUWn

New article: A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome https://t.co/A9nA9c8pId #AML #leusm #hematology https://t.co/QaVfNXrscl

$APVO Reports APVO436 Monotherapy Is Active In Patients Who Have Relapsed Acute Myeloid Leukemia Or Myelodysplastic Syndrome https://t.co/jjFejeh8dS https://t.co/bKRuMCgMQW

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.